<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1726-8958</journal-id>
<journal-title><![CDATA[Revista Médica La Paz]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. La Paz]]></abbrev-journal-title>
<issn>1726-8958</issn>
<publisher>
<publisher-name><![CDATA[Colegio Médico de La Paz]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1726-89582021000200042</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[TAQUICARDIA TIPO TORCIDA DE PUNTAS SECUNDARIA A PROLONGACIÓN DEL INTERVALO QT POR USO DE AMITRIPTILINA A PROPÓSITO DE UN CASO]]></article-title>
<article-title xml:lang="en"><![CDATA[TORSADES DE POINTES DUE TO PROLONGED QT INTERVAL BY AMITRIPTILIN USE]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alanoca]]></surname>
<given-names><![CDATA[Gladys]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arce]]></surname>
<given-names><![CDATA[Mauricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Tórax  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Tórax  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2021</year>
</pub-date>
<volume>27</volume>
<numero>2</numero>
<fpage>42</fpage>
<lpage>48</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S1726-89582021000200042&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S1726-89582021000200042&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S1726-89582021000200042&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El intervalo QT representa la actividad eléctrica ventricular, tanto la despolarización como la repolarización. Definimos como intervalo QT prolongado a una medida del QT corregido &gt; 450 ms en varones y &gt; 470 ms en mujeres. Se diferencian 2 grandes grupos dentro del síndrome del QT prolongado: el congénito, asociado con mutaciones en determinados genes, y la variante adquirida. El síndrome de QT prolongado es un conjunto de entidades infrecuentes que se manifiestan en el ECG por la prolongación del intervalo QT y la predisposición a la taquicardia ventricular polimórfica. Una de las principales etiologías del síndrome de QT congénito adquirido es el uso de fármacos prolongadores del intervalo QT. En la actualidad la lista de fármacos que pueden prolongarlo a dosis terapéuticas es amplia y está en continuo crecimiento. La prolongación del intervalo QT puede predisponer a la aparición de taquicardia ventricular polimórfica grave denominada torcida de puntas (TdP), cuya aparición no es muy frecuente, pero es causa de muerte súbita. En el presente reporte presentamos un caso de desarrollo de torcida de puntas debido a uso de amitriptilina.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT The QT interval representas ventricular electrical activity, both depolarization and repolarization. We define a prolonged QT interval as a corrected QT measurement&gt; 450 ms in men and&gt; 470 Two major groups are distinguished within the long QT syndrome: congenital, associated with mutations in certain genes, and the acquired variant. Long QT syndrome is a rare group of entities that are manifested on ECG by prolongation of the QT interval and predisposition to polymorphic ventricular tachycardia. One of the main etiologies of acquired congenital QT syndrome is the use of QT- prolonging drugs. At present, the list of these is extensive and is constantly growing. Prolongation of the QT interval can predispose to the development of severe polymorphic ventricular tachycardia called torsades de pointes (TdP), which is not a very common presentation but is a cause of sudden death. In this report, we present a case of the development of severe polymorphic ventricular tachycardia due to the use of amitriptyline.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Síndrome de QT prolongado adquirido]]></kwd>
<kwd lng="es"><![CDATA[torcida de puntas]]></kwd>
<kwd lng="es"><![CDATA[amitriptilina]]></kwd>
<kwd lng="en"><![CDATA[Acquired long QT syndrome]]></kwd>
<kwd lng="en"><![CDATA[torsades de pointes]]></kwd>
<kwd lng="en"><![CDATA[amitriptylin]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fajas]]></surname>
<given-names><![CDATA[C.C.]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[U. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Ibáñez]]></surname>
<given-names><![CDATA[P. J.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome de QT largo secundario a fluoxetina]]></article-title>
<source><![CDATA[Semerg]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Vieira]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Moll]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Citalopram, escitalopram y QT largo ¿alerta o alarma?. Rev Psiquiatr Salud]]></article-title>
<source><![CDATA[Ment (Barc.)]]></source>
<year>2014</year>
<volume>7</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>147-50</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ch.]]></surname>
<given-names><![CDATA[Hocht]]></given-names>
</name>
<name>
<surname><![CDATA[Opezzo]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Taira]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intervalo QT prolongado inducido por fármacos desde el punto de vista de un farmacólogo]]></article-title>
<source><![CDATA[Revista Argentina de Cardiología]]></source>
<year>2004</year>
<volume>72</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Asensio]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Acunzo]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Uribe]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence]]></article-title>
<source><![CDATA[J Interv Card Electrophysiol]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giudicessi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Noseworhty]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ackerman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19]]></article-title>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>2020</year>
<volume>95</volume>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="">
<source><![CDATA[Centro de Información de Medicamentos Servicio de Farmacia HSJD]]></source>
<year>2015</year>
<volume>5</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Celaya]]></surname>
<given-names><![CDATA[M.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[B. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medicamentos y prolongación del intervalo QT]]></article-title>
<source><![CDATA[Boletín de Información Farmacoterapéutica de Navarra]]></source>
<year>2013</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Intervalo QT en ECG de. en ECG]]></source>
<year>2007</year>
<edition>2</edition>
<page-range>400-2</page-range><publisher-name><![CDATA[Marban libros]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palazzolo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Electrocardiografia Basica]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Franco]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual latinoamericano de electrocardiografía clínica]]></source>
<year>2012</year>
<edition>1</edition>
<page-range>21-37</page-range><publisher-loc><![CDATA[Maracaibo- Venezuela ]]></publisher-loc>
<publisher-name><![CDATA[astro data]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tisdale]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Jaynes]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Kingery]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Mourad]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Trujillo]]></surname>
<given-names><![CDATA[TN]]></given-names>
</name>
<name>
<surname><![CDATA[Overholser]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and validation of a risk score to predict QT interval prolongation in hospitalized patients]]></article-title>
<source><![CDATA[Circ Cardiovasc Qual Outcomes]]></source>
<year>2013</year>
<volume>6</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>479-87</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alargamiento del intervalo QT por citalopram, escitalopram y amitriptilina]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2013</year>
<volume>346</volume>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[B. S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Unidad de Salud Mental Infanto-juvenil del Hospital Sierrallana. Torrelavega, Cantabria. Manejo de psicofármacos]]></article-title>
<source><![CDATA[ADOLESCERE. Revista de Formación Continuada de la Sociedad Española de Medicina de la Adolescencia]]></source>
<year>2014</year>
<volume>II</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
